September 28, 2021

Fast-acting Psychedelics to Treat the Most Number of Patients | BioMind Labs (BMND)

Midas Letter
Midas Letter
Fast-acting Psychedelics to Treat the Most Number of Patients | BioMind Labs (BMND)
/

BioMind Labs Inc (NEO:BMND, OTCMKTS:CRSWF) has a long history of working with psychedelic compounds. Its scientific research date all the way back to 2006 in Brazil. Its initial workings were to understand the impact of Ayahuasca on the brain. Through these studies, BioMind’s scientists discovered the potential for Ayahuasca derivatives to help neurological and psychiatric disorders. Now, with the former CEO of ICC International Cannabis Corp at the helm, the company is creating novel psychedelic formulations & delivery systems to try to treat the most number of patients.

“BioMind is born out of the combination of very serious and successful businessman on one hand and very successful and experienced scientists. What we are doing together is basically to become the gamechanger in the psychedelic industry – BioMind Labs Scientific and Clinical Advisor Dr. Draulio Barros de Araujo

To treat the most number of patients, drug administration has to be less general and very specific. BioMind understands that a four-hour ayahuasca trip does not benefit the majority of people searching for psychotherapy help. In this vein, BioMind has a large drug pipeline involving tweaked psychedelic compounds to reduce the experience time of the original drugs. BioMind has also patented nanotechnology delivery mechanisms to control for bioavailability, variability, side effects, etc.

“Depending on the condition we are going to treat, we are going to use a different substance and a different route of administration” – BioMind Labs Scientific and Clinical Advisor Dr. Draulio Barros de Araujo

BioMinds pipeline includes drug formulations such as ayahuasca, DMT, psilocybin, mescaline, and 5-MeO-DMT.

Watch the full CEO interview to understand the history of how BioMind scientists discovered how psychedelics could be a game-changer in mental health and the company’s growing novel drug pipeline.

Transcript

00:00 – BioMind Labs Dr. Draulio Barros de Araujo
00:50 – BioMind history & overview
06:15 – Combination of science & former CEO of ICC Labs
07:43 – Novel compounds & administration
12:13 – Drug pipeline
13:13 – Clinical trial results
14:15 – Future global clinical trials
15:15 – Where BioMind is based

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.